Cost-effectiveness analysis of ferric carboxymaltose in iron-deficient patients with chronic heart failure in Sweden

Journal of Medical Economics
Thomas Hofmarcher, Sixten Borg

Abstract

Iron deficiency is a common but treatable comorbidity in chronic heart failure (CHF) that is associated with impaired health-related quality-of-life (HRQoL). This study evaluates the cost-effectiveness of the intravenous iron preparation ferric carboxymaltose (FCM) for the treatment of iron deficiency in CHF from a Swedish healthcare perspective. A cost-effectiveness analysis with a time horizon of 24 weeks was performed to compare FCM treatment with placebo. Data on health outcomes and medical resource use were mainly taken from the FAIR-HF trial and combined with Swedish cost data. An incremental cost-effectiveness ratio (ICER) was calculated as well as the change in per-patient costs for primary care and hospital care. In the FCM group compared with placebo, quality-adjusted life years (QALYs) are higher (difference = 0.037 QALYs), but so are per-patient costs [(difference = SEK 2789 (€303)]. Primary care and hospital care equally share the additional costs, but within hospitals there is a major shift of costs from inpatient care to outpatient care. The ICER is SEK 75,389 (€8194) per QALY. The robustness of the result is supported by sensitivity analyses. Treatment of iron deficiency in CHF with FCM compared with placebo is ...Continue Reading

References

Nov 21, 1997·Medical Care·P Dolan
May 30, 2002·European Journal of Heart Failure·Simon StewartJohn J J V McMurray
May 30, 2002·European Journal of Heart Failure·C M J ClineUNKNOWN Swedish Society of Cardiology Working Group for Heart Failure
Aug 9, 2002·European Journal of Heart Failure·Charles Cline
Jun 1, 2005·Lancet·John J V McMurray, Marc A Pfeffer
Nov 8, 2005·Scandinavian Journal of Primary Health Care·Björn AgvallUlf Dahlström
Aug 30, 2008·Journal of the American College of Cardiology·Hessel F GroenveldPeter van der Meer
Nov 26, 2009·Journal of Renal Care·Iain C Macdougall
Nov 19, 2009·The New England Journal of Medicine·Stefan D AnkerUNKNOWN FAIR-HF Trial Investigators
Dec 19, 2009·Circulation·UNKNOWN WRITING GROUP MEMBERSUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Jun 24, 2010·European Heart Journal·Ewa A JankowskaPiotr Ponikowski
Nov 9, 2010·Current Heart Failure Reports·Donald S SilverbergDov Wexler
Jun 2, 2011·Nature Reviews. Cardiology·Dirk J van VeldhuisenIain C Macdougall
Apr 24, 2012·European Journal of Heart Failure·Iain C MacdougallStefan D Anker
Oct 31, 2012·European Journal of Heart Failure·Björn AgvallUlf Dahlström
Mar 30, 2013·American Heart Journal·Ijsbrand T KlipEwa A Jankowska
May 7, 2013·European Journal of Heart Failure·Ramin ZarrinkoubThomas Kahan

❮ Previous
Next ❯

Citations

Dec 17, 2015·Heart, Lung & Circulation·Christopher C Y WongAndrew P Sindone
Jun 23, 2015·International Journal of Molecular Sciences·Donald S SilverbergDoron Schwartz
Oct 21, 2015·The Canadian Journal of Cardiology·Eileen O'MearaSerge Lepage
Nov 21, 2018·Scandinavian Cardiovascular Journal : SCJ·Thomas HofmarcherCecilia Linde
Oct 4, 2019·Journal of Comparative Effectiveness Research·Carla Rognoni, Simone Gerzeli
Sep 10, 2021·International Journal of Clinical Pharmacy·Chuin Khai LimCorinne Mirkazemi
Oct 17, 2021·European Journal of Heart Failure·Gema MiñanaJulio Núñez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.